Bracanat (Olaparib) 150 mg
Bracanat 150 mg is a targeted therapy drug containing Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor.
Manufacturer: Natco Pharma (India). Generic equivalent of Lynparza.
Mechanism: Exploiting Genetic Weakness
Olaparib exploits a defect in the DNA repair pathway of cancer cells (synthetic lethality). It is particularly effective in cancers harboring BRCA1 or BRCA2 mutations. By blocking the PARP enzyme, it prevents cancer cells from repairing their DNA, leading to cell death.
✅ Key Benefit: Leading maintenance therapy for ovarian cancer.
Indicated for the treatment of:
- Ovarian Cancer: Maintenance treatment for recurrent or advanced disease (especially BRCA-mutated).
- Breast Cancer: Metastatic HER2-negative, BRCA-mutated cancer.
- Pancreatic Cancer: Maintenance treatment for metastatic BRCA-mutated cancer.
- Prostate Cancer: Metastatic castration-resistant prostate cancer with HRR gene mutations.
Strength: 150 mg tablet.
Standard Dosage: 300 mg twice daily.
⚠️ PILL COUNT:
- Take 2 tablets in the morning.
- Take 2 tablets in the evening.
- Total: 4 tablets per day.
Instructions: Swallow whole. Do not chew, crush, or split. Avoid grapefruit and Seville oranges during treatment.
- Pregnancy and breastfeeding (Highly teratogenic).
- Severe renal impairment.
- Concomitant use of live vaccines.
Hematologic Toxicity is common.
Patients often experience Anemia (low red blood cells), Neutropenia, or Thrombocytopenia. Monthly blood tests are mandatory to monitor blood counts.
Other effects: Nausea (very common), fatigue, vomiting, and dysgeusia (taste changes).
What Customers Say
No reviews yet
Your review can be the first!